ReNTox™ Botulinum Toxin A Injection
Pharmaceutical-grade neurotoxin formulation by Pharma Research Bio (KFDA-approved). Contains 200 Units/vial of Botulinum Toxin Type A derived from Clostridium botulinum CBFC26 strain. Clinically demonstrated 92% patient satisfaction rate with 3-day onset and 6-8 month duration in 85% of cases. Gold standard in Asian aesthetic medicine since 2018.
PRECISION THERAPEUTIC ADVANTAGES
✓ Ultra-low diffusion (0.5cm²)
✓ 98% pure toxin concentration
✓ Albumin/gelatin-free formula
✓ ISO 13485 certified production
✓ 36-month stability profile
✓ <1% adverse reaction rate
✓ pH-balanced 6.8±0.3 solution
✓ Dual cosmetic/therapeutic action
ADVANCED FORMULATION TECHNOLOGY
• Proprietary Low-Diffusion Matrix™ with 150kDa complex size
• Enhanced target specificity via pH-stabilized configuration
• Terminal filtration (0.2μm) sterilization process
• Batch-tested potency (LD50 assay validated)
PHARMACEUTICAL SPECIFICATIONS
• Presentation: Lyophilized powder + diluent
• Vial content: 200 Units (±5%) Botulinum Toxin A
• Excipients: Sodium chloride, sucrose
• Storage: 2°C-8°C (validated 36-month stability)
• Packaging: Type I glass vial (3cc) with bromobutyl stopper
CLINICAL PROTOCOL
1. Reconstitute with 0.9% sterile saline (2.5ml/vial)
2. Administer within 4 hours post-reconstitution
3. Standard dosage: 4-5 Units per 0.1ml injection
4. Max recommended dose: 200 Units/session
5. Treatment interval: ≥3 months between sessions
Medical Notice: Rx-only product. Must be administered by licensed practitioners. Contraindicated in neuromuscular disorders. 0.01% anaphylaxis risk reported. Store refrigerated (2-8°C). Batch number: [See vial label]. Manufactured under KFDA GMP guidelines (Cert. No. 2024-38215).Results may vary based on individual biochemistry and treatment compliance.
Reviews
There are no reviews yet.